NEWS & MEDIA

Prof. Matthias Schönermark joined HeartGenetics Advisory Board

Prof. Matthias Schönermark joined HeartGenetics Advisory Board

HeartGenetics is proud to announce the new member of the advisory board, Prof. Matthias Schönermark. Our multidisciplinary body of high level experts provide specialist advice and insight to maximise the clinical value and impact of HeartGenetics products. Prof. Matthias Schönermark, a highly skilled surgeon and healthcare enterpreneur, is the most recent, and an extremely valuable, HeartGenetics consultant.

Prof. Schönermark (M.D., Ph.D) is a trained head and neck surgeon, an entrepreneur and a strategy consultant to the health care industry for more than 15 years.
After his clinical career in the Department of Otorhinolaryngology at Hannover Medical School and research assignments in clinical oncology at Dartmouth Medical School in Hanover/NH and the Columbia University New York, he joined The Boston Consulting Group, where he became manager and founded the European Payer Provider Group, BCG’s health care strategy think tank.

He became Interim-CEO at a midcap biotech company which he reconstructed and joined afterwards A.T.Kearney’s Strategy Practice as an Associate Director for one and a half years. Ten years ago, he founded SKC, which has become one of the leading strategy consultancies in the healthcare field.

His main fields of interest are developing new businesses, designing market access strategies and shaping the collaborative culture of innovative organizations from within. He is a qualified neuroleadership coach and holds a certificate in systemic therapy. Prof. Schönermark teaches Strategic Leadership and Health Care Entrepreneurship in Universities and Business Schools in Germany, The Netherlands and the USA.

He is member of several advisory bodies and committees, e.g. the health industry working group of the German Industry Association, the working group “health industry” of the Lower-Saxony Ministry of Trade and Commerce, the supervisory board of the Center for Biomedical Technology and Innovation (BiomeTI).

< Back to News Page
Share this article